ACM
GYRE icon

Aster Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Aster Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,447
Closed -$10.6K – 1133
2025
Q2 		$10.6K Buy
1,447
+1,388
+2,353% +$12.1K ﹤0.01% 786
2025
Q1 		$684 Buy
+59
New +$647 ﹤0.01% 1190

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aster Capital Management's GYRE Position: Q3 2025 in Review

Aster Capital Management sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 1,447 shares — an estimated $10.6K sold.

Aster Capital Management first reported a position in GYRE in Q1 2025 and held it in 2 quarters. The position peaked at $10.6K in Q2 2025. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

  • Aster Capital Management reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Aster Capital Management sold 1,447 Gyre Therapeutics shares in Q3 2025, an estimated $10.6K.
  • Aster Capital Management first reported a position in Gyre Therapeutics in Q1 2025 and held it in 2 quarters.
  • Aster Capital Management's Gyre Therapeutics position peaked at $10.6K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Aster Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.